Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Jake Dunning, Honorary Visiting Research Fellow in Tropical Medicine (ERGO) and Deputy Programme Director for High Consequence Infectious Diseases, NHS England, is appointed MBE for services to Clinical Research. Dr Dunning led clinical trials during the terrible Ebola epidemic in West Africa.

Jake Dunning
Dr Jake Dunning, Honorary Visiting Research Fellow at the Centre for Tropical Medicine and Global Health, has been awarded an MBE in the New Year's Honours list. The award recognises his services to clinical research, particularly his contributions to Ebola research efforts. Jake joined the Epidemic diseases Research Group Oxford (ERGO) in October 2014, as part of the RAPIDE trial team studying potential treatments for Ebola virus disease in West Africa. The trials, led by Prof Peter Horby, evaluated two candidate drugs at Ebola treatment centres in Liberia and Sierra Leone. Jake was the Field Lead for the trials, based in West Africa, and worked with over 40 researchers from 10 countries, including doctors and nurses from the affected countries.
Following completion of the trials in 2015, Jake moved to a new full time post as Consultant in Infectious Diseases at the National Infection Service, Public Health England. However, he continues to work with ERGO on preparedness and response activities for outbreak research. Additionally, Jake is the NHS England Deputy Programme Director for High Consequence Infectious Diseases, which includes diseases such as viral haemorrhagic fever, avian influenza, and pneumonic plague. He also practises clinical infectious diseases at the Royal Free Hospital, London. Along with other trial team members, Jake received a British Government Ebola Service Medal in 2015, and his international colleagues were recognised with the award of Oxford Ebola service medals.
On receiving his award, Jake said "I am very grateful to have received this honour, mindful that I was part of a brilliant and dedicated team. Without the extraordinary support of colleagues in the field and in Oxford, these unique and very challenging trials would not have happened. We are now applying the skills and lessons learned to improving outbreak preparedness, response and research activities for high consequence infections, both overseas and in the UK. I am indebted to Peter Horby and the Centre, for having provided me with such an amazing opportunity.

The full story is available on the University of Oxford website

Similar stories

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.